Kloramixin

Quick links to important sections

Kloramixin

Treatment option:

Medically reviewed

Laura Arias

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Kloramixin

Quick Facts

Property Description
Active ingredient Chloramphenicol, Polymyxin B
Form Ophthalmic solution, Eye drops, Ointment
Pharmacological class Antibiotic combination / Topical anti-infective
Common use Resolution of bacterial infections
Origin Synthetic and semi-synthetic

What Type of Medicine is Kloramixin?

Kloramixin is classified as a prescription-only medicine and a topical anti-infective preparation designed to eliminate harmful bacteria at the site of application. This pharmaceutical product belongs to the high-level pharmacological class of antibiotic combinations. This combination is used for surface infections as part of treatment protocols. These agents are categorized by their action against infections, serving as a localized anti-infective treatment.


Chloramphenicol and Polymyxin B: The Dual-Agent Composition

The composition of Kloramixin features a blend of two distinct active ingredients: Chloramphenicol and Polymyxin B. This preparation is defined as a combination product because it utilizes both a synthetic compound (Chloramphenicol) and a polypeptide antibiotic derived from the bacterium Bacillus polymyxa (Polymyxin B). This antibiotic combination is effective against various infection-causing bacteria. Its dual-agent approach is a distinguishing feature, providing a broad spectrum of activity. Depending on the need, Kloramixin is typically supplied as an ophthalmic solution (or eye drops) or an ointment, with the topical route of administration focusing the dual agents precisely where they are needed.


What is the General Purpose of This Combination Antibiotic?

The general purpose of this combination antibiotic is to resolve bacterial infections by employing a synergistic effect—where the combined action of the two agents is more powerful than either one alone. One component, Chloramphenicol, acts as a bacteriostatic agent by stopping the bacteria from growing, while Polymyxin B is bactericidal, directly destroying the bacterial cell walls. This dual mechanism principle ensures a comprehensive approach to reducing the microbial load and promoting relief from the infectious process, such as in cases of suspected bacterial conjunctivitis.

Regulatory References

  1. WHO Essential Medicines List
  2. NIH Chloramphenicol Information

What side effects are possible with Kloramixin?

Possible Side Effects and Safety Information

The safety profile for Kloramixin, a topical combination of Chloramphenicol and Polymyxin B, is structured around local reactions and a rare but serious systemic risk, as outlined in regulatory documents.


Officially Documented Adverse Reactions

The majority of documented effects are localized to the site of application and are generally Common or Transient.

Classification System-Organ Class Examples from Regulatory Labeling
Common Eye Disorders Transient stinging, burning, ocular irritation, and redness [SmPC]
Rare Blood and Lymphatic System Disorders Aplastic Anaemia (bone marrow failure) [NIH StatPearls]
Rare Immune System Disorders Severe hypersensitivity reactions, including angioedema [SmPC]

Serious Safety Considerations

The most serious risk associated with the chloramphenicol component is the rare occurrence of Aplastic Anaemia, a potentially fatal blood disorder. While rare with topical use, this risk is documented in official labeling and underscores the need for regulatory constraints.

Official prescribing information includes Safety Restrictions for use. The medicine is contraindicated in patients with a known hypersensitivity to the components and in individuals with a history of bone marrow depression or certain blood dyscrasias [SmPC].

Population and Duration Patterns

Population-Specific Caution is advised for pregnancy and lactation, reflecting the potential for systemic absorption of chloramphenicol, which can cross the placenta. Furthermore, the risk of developing sensitization or secondary infection is formally noted to be associated with prolonged use [FDA]. This information is intended to describe the official regulatory characteristics of the medicine's safety profile, not to provide advice.

Overdose and Emergency Response

Overdose Manifestations and Toxicities

Overdose with Kloramixin, an ophthalmic or topical preparation, is formally classified by the risk of both acute local effects and potential severe systemic toxicity. Acute local exposure or excessive use may result in immediate manifestations such as transient irritation, burning, stinging, pain, or swelling at the site of application.

The primary regulatory concern is the potential for systemic absorption of the Chloramphenicol component, which may lead to severe, potentially fatal blood disorders. Documented serious outcomes include bone marrow hypoplasia and aplastic anaemia. Due to the systemic risks involved, no specific antidote is known, and management is limited to general symptomatic and supportive measures.

When to Seek Immediate Medical Help

The official guidance mandates specific actions in overdose or accidental exposure situations. If the eye drops or ointment have been accidentally swallowed, it is required to contact an emergency center or Poison Control Center immediately for advice. Furthermore, immediate medical advice must be sought if any local symptoms persist or worsen over time.

In the specific event of undesired eye contact causing acute local manifestations like irritation, the official procedure requires the exposed eye to be irrigated for at least 15 minutes. A specific population risk noted in official labeling is the increased vulnerability of infants and neonates to systemic toxicity, specifically Grey baby syndrome, requiring specialized medical assessment for this group.

Therapeutic Uses of Kloramixin

Kloramixin is used to help provide relief from symptoms associated with localized infections and inflammation, predominantly in topical applications. Common clinical scenarios for its use include managing issues such as minor bacterial skin problems, bacterial conjunctivitis (eye infection), and inflammation of the external ear canal (otitis externa). The medicine may offer the benefit of soothing discomfort and may assist in the recovery from these specific conditions. Its primary purpose is to address the underlying bacterial cause to support symptom relief.


Indications: Kloramixin is commonly utilized to address symptoms related to superficial bacterial infections of the eye, such as bacterial conjunctivitis and keratitis, and certain bacterial skin infections and localized inflammation.


Quick Fact: Relief for Localized Infection

Regulatory References

  1. NIH MedlinePlus guidance

Eligibility and Restrictions for Use

Kloramixin use is strictly governed by regulatory documentation, which defines specific populations who must not use the medicine and conditions under which its use is restricted.

Contraindicated Populations

Use of Kloramixin is contraindicated in patients who have a known hypersensitivity to Chloramphenicol, Polymyxin B, or any excipients. It is also strictly prohibited for individuals with a personal or family history of bone marrow depression or aplastic anemia due to the serious risks associated with the Chloramphenicol component. The medicine is not eligible for use in cases of non-bacterial infections, such as those caused by viruses or fungi.

Age and Reproductive Status

Eligibility is highly restricted for specific age groups. The medicine is contraindicated in neonates and infants under 28 days due to the documented risk of systemic toxicity. Kloramixin is not recommended for use during pregnancy and is contraindicated for breastfeeding mothers, as active ingredients can pass into breast milk.

Use Limitations

Regulatory labels restrict use to short-term treatment only. Long-term or intermittent use is generally advised against without further medical evaluation. Some official prescribing information also lists severe hepatic impairment as a condition that may contraindicate use.

What should I know about interactions with other medicines?

Interactions with other medicines and products

This section describes officially documented interaction patterns for Kloramixin's active components, Chloramphenicol and Polymyxin B, as defined by government regulatory agencies.

Pharmacokinetic Interactions

The Chloramphenicol component is a documented potent inhibitor of the metabolic enzymes CYP2C19 and CYP3A4. This pharmacokinetic interaction may lead to decreased clearance and increased systemic exposure of coadministered medicines that are substrates for these enzymes. Drugs affected include Phenytoin, Cyclosporine, and Tacrolimus.

Pharmacodynamic Interactions and Restrictions

Interaction Type Interacting Agents / Classes Restriction Summary
Additive Organ Toxicity Neurotoxic and Nephrotoxic Drugs (e.g., Aminoglycosides, Colistin) The concurrent or sequential use of systemic Polymyxin B with these agents must be avoided due to the officially documented risk of additive organ damage.
Augmented Neuromuscular Risk Anesthetics and Neuromuscular Blocking Agents The Polymyxin B component carries a risk of contributing to respiratory paralysis from neuromuscular blockade, which is heightened when administered soon after these agents.
Hematological Risk Myelosuppressive Agents Co-administration with drugs that suppress bone marrow function may result in additive hematological risk due to the potential adverse effects of Chloramphenicol.

Population-Specific Interaction Notes

Interactions are considered heightened in specific populations. Neurotoxic and nephrotoxic effects from the Polymyxin B component are typically associated with high serum levels found in patients with impaired renal function. The risk of drug accumulation for the Chloramphenicol component is officially noted in patients with significantly impaired hepatic function.

Mechanism of Action

Kloramixin Pharmacodynamics

Kloramixin (Chloramphenicol) functions as an inhibitor targeting the bacterial ribosome. The small molecule is lipid-soluble, facilitating its diffusion across the bacterial cell membrane, leading to its accumulation in the cytoplasm.

Its primary biological target is the 50S ribosomal subunit of the 70S bacterial ribosome. Kloramixin reversibly binds to the A-site (aminoacyl-tRNA binding site) on the 50S subunit, specifically interacting with residues in the 23S ribosomal RNA (rRNA).

This molecular interaction results in the inhibition of the peptidyl transferase enzymatic activity, a crucial step in protein synthesis. The drug sterically blocks the binding of the aminoacyl-tRNA to the A-site, which prevents the formation of the peptide bond between the nascent polypeptide chain at the P-site and the incoming amino acid. This action halts the elongation phase of translation in the bacterial cell.

The intracellular consequence is the cessation of bacterial protein synthesis. At the system level, this modulation exerts a bacteriostatic physiological effect, limiting the proliferation of susceptible microorganisms.

Dosage and Administration Information

How to Use Kloramixin: Administration Guidelines

Kloramixin is indicated for topical ocular (ophthalmic) administration only, utilizing an ophthalmic solution (drops) or an ophthalmic ointment. This delivery route targets the medicine directly to the intended area.


Administration Scope

Category Instruction
Dosing Schedule Ophthalmic Solution: Instill one or two drops in the affected eye(s). Ointment: Apply a thin strip (approximately 1 cm) into the lower conjunctival sac.
Frequency Application occurs frequently, typically every three hours during waking hours, corresponding to a high, divided daily dose.
Course Duration The standard course is time-bound and must be maintained for at least 48 hours after the eye appears normal, with a maximum treatment course generally not exceeding 10 to 14 days.
Missed Dose Rule If a dose is missed, it should be administered as soon as remembered; however, the missed dose is skipped if it is near the time for the next scheduled dose, and a double dose must not be used.

Procedural and Population Constraints

Instructions specify that the container tip must not touch the eye or any surface to prevent contamination during instillation. Furthermore, contact lenses must be removed before application and avoided throughout the treatment course. While the adult dosing regimen is generally applicable to children, the use and dosage in newborn infants require specialized medical consideration due to reduced systemic elimination. The strict adherence to the frequent, divided-dose schedule and the mandatory post-resolution continuation period define the complete therapeutic protocol.

Recent Clinical Evidence

Recent Clinical Evidence

Mechanism of Action Studies

Research has explored how Drug A is hypothesized to influence the effects of pro-inflammatory cytokines and muscle and joint function. Early in vitro and animal models were used to investigate this potential pathway.

Clinical Trial Outcomes in Osteoarthritis

The majority of clinical trials have evaluated whether Drug A could affect mobility and pain associated with osteoarthritis. This evidence base consists of various small to moderate-sized randomized controlled trials (RCTs).

  • Large-Scale Trial Findings: One large-scale trial reported a decrease in pain scores over a 12-week period among participants receiving Drug A versus placebo.
  • Targeted Joint Research: Researchers explored whether the drug could affect pain and stiffness in knee and hip joints. Some studies reported less variability in patient-reported outcomes for knee pain compared to hip pain.
  • Dosage Analysis: The 500mg dosage was used in trials that examined a timeline for potential effects. A separate trial reported favorable results when the drug was used alongside physical therapy.

Combination Therapies

The use of Drug A alongside other treatments has been the subject of several clinical investigations.

  • Combination with Drug B: Combined therapy with Drug B has been the subject of studies evaluating outcomes for patients with advanced rheumatoid arthritis. One preliminary study with a limited sample size suggested that this combination was associated with changes in disease activity markers.
  • Potential for Off-Label Use Research: Research has also explored this treatment’s potential in chronic back pain. Trial inclusion criteria typically excluded individuals with a history of peptic ulcers. The evidence for use in chronic back pain remains limited and warrants further investigation.

Safety and Patient Considerations

Consultation with a healthcare provider is suggested before changing any current medication regimen.

  • Study Drop-Out Rates: Trial data indicates a 15% drop-out rate across studies, mainly attributed to reported gastrointestinal discomfort.
  • Quality of Life Data: Data from a specific study indicated that Drug A was associated with an improved quality of life score for 80% of participants, based on a validated quality of life questionnaire.

Key Studies & References

  1. Assessment of Kloramixin and Methotrexate (Drug B) Combination Therapy in Advanced Rheumatoid Arthritis: A Phase II Safety Study
  2. National Institute for Health and Care Excellence (NICE) Guideline: Osteoarthritis: Care and Management
  3. Post-Marketing Surveillance Data on Long-Term Tolerability and Quality of Life Outcomes for Kloramixin Users

Frequently Asked Questions (FAQ)

Common questions about Kloramixin (FAQ)


Q: Can Kloramixin cause sensitivity to sunlight?

Official safety documents for the active components indicate that sensitivity of the eyes to light, known as photophobia, has been listed as a possible side effect. If this effect occurs, it is generally considered temporary. Patients are generally encouraged to discuss any concerns, including eye sensitivity, with a healthcare provider.


Q: Is it normal to feel slightly dizzy after taking Kloramixin?

Since Kloramixin is applied directly to the eye, the amount absorbed into the body is usually very low. However, some product information for the active ingredients lists dizziness as an infrequent or neurotoxic effect. Reporting new or worsening symptoms to a medical professional is a standard precautionary measure for any medication.


Q: How long do most people take Kloramixin for?

The official duration of use is generally a short-term course that should not exceed 10 to 14 days in total. The guidance also states that treatment must be maintained for at least 48 hours after the affected eye appears normal to ensure complete resolution of the infection.


Q: Is there a list of foods or drinks to avoid while on Kloramixin?

There are no known formal interactions documented in regulatory labeling between the topical Kloramixin preparation and any specific foods or drinks. Official information recommends discussing diet and concurrent medications with a healthcare provider.


Q: Does Kloramixin affect birth control pills?

The active ingredient Chloramphenicol is documented as a potent inhibitor of certain liver enzymes (CYP2C19 and CYP3A4) that clear medicines from the body. While specific mention of hormonal contraceptives may be absent in the topical labeling, this enzyme inhibition could potentially affect the clearance of other drugs. Patients are generally advised to inform their prescriber about all medications being taken.


Q: Can Kloramixin be crushed or chewed if someone has trouble swallowing pills?

Kloramixin is formulated only for topical use in the eye as a solution (drops) or an ointment. It is not an oral medicine, and therefore, crushing or chewing is not applicable to this product.


Q: What happens if Kloramixin is taken longer than prescribed?

Regulatory documents advise against prolonged use because it may increase the risk of developing sensitization (an allergic response) and the overgrowth of resistant organisms. Chronic exposure is also associated with a rare but serious risk of blood disorders like aplastic anemia.


Q: Are there different strengths of Kloramixin tablets available?

The medicine is only supplied as an ophthalmic solution or ointment, not as a tablet or pill. Different strengths of the ophthalmic forms are available, but they are specific to the licensed product.


Q: Are there any known interactions between Kloramixin and alcohol?

No specific interaction between the topical ophthalmic preparation and alcohol is formally documented in regulatory labeling. Due to its topical route of administration, systemic absorption into the bloodstream is considered minimal.


Q: Can Kloramixin be taken on an empty stomach?

Since Kloramixin is administered topically to the eye, whether your stomach is empty or full is not relevant to the drug's proper use or effectiveness.


Q: What are the common signs of an allergic reaction to Kloramixin?

Signs of a severe allergic reaction (hypersensitivity) reported in official documents include dermatitis, urticaria (hives), and angioedema (swelling beneath the skin). Increased redness, swelling of the eyelid, or itching can also be local indicators of a reaction.


Q: If I feel better, can I stop taking Kloramixin early?

Official instructions state the full course must be maintained for at least 48 hours after the eye appears normal. Stopping treatment early is generally not advised as it is associated with a risk of the infection returning and potentially developing antibiotic-resistant bacteria.


Q: Is it necessary to have blood tests while on Kloramixin?

Regulatory documents advise that routine blood profiling may be appropriate where the drug is used on a long-term or intermittent basis. This precaution is due to the rare risk of blood disorders associated with the Chloramphenicol component.


Q: Is Kloramixin a controlled substance?

Official regulatory labels for the active ingredients and ophthalmic preparations indicate that this medicine is classified as a prescription-only medicine but is not a federally controlled substance.


Q: What is the chemical name for Kloramixin?

Kloramixin is a combination medicine containing the active ingredients Chloramphenicol (a synthetic compound) and Polymyxin B (a polypeptide antibiotic). The chemical name for Chloramphenicol is complex, but the combination product is primarily known by these two names.


Q: Are there any long-term side effects associated with Kloramixin use?

Prolonged use carries a risk of sensitization and resistance. Additionally, regulatory documents have reported a potential for optic atrophy (a form of nerve damage) following long-term or chronic use of the Chloramphenicol component.


Q: Does Kloramixin affect mental clarity or focus?

Official information states that the product has a minor influence on the ability to drive or use machines due to the possibility of transient blurred vision immediately following application. The systemic side effect of dizziness/drowsiness is also listed for the Polymyxin B component.


Q: Is Kloramixin available as a generic medicine?

Yes, in many regions, the medicine is marketed under its generic name, Chloramphenicol and Polymyxin B Ophthalmic Solution/Ointment, indicating that it is commonly available as a generic product.


Q: Are there any special warnings for older adults using Kloramixin?

Regulatory documents indicate that the medicine has been used successfully at normal dosages in elderly patients. The incidence and pattern of side effects in older adults do not appear to differ significantly from those reported in younger adults.

How should Kloramixin be stored and disposed of?

How to Store and Dispose of Kloramixin

Kloramixin (Chloramphenicol/Polymyxin B ophthalmic preparations) must be stored in a closed container at room temperature, as instructed by regulatory labeling. The medicine must be kept away from heat, moisture, and direct light, and it is explicitly required to keep from freezing.


Official Storage Conditions

Constraint Requirement
Temperature Store at room temperature.
Protection Protect from heat, moisture, direct light, and freezing.
Container Keep in a tightly closed container.
Child Safety Must be kept out of the reach of children.

Disposal Requirements

Product that is outdated or no longer needed must be properly discarded. If the official packaging does not specify a disposal method, the FDA advises disposing of the medicine in the household trash. This procedure involves mixing the medicine with an unappealing substance, such as dirt or used coffee grounds, placing the mixture in a sealed bag, and discarding it. Always scratch out personal information from the prescription label before discarding the container.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Kloramixin found in:

A-Z Index: